エリスロポエチン（EPO）の世界市場レポート 2024

エリスロポエチン（EPO）の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には12.6%の年間複合成長率（CAGR）で309億2,000万米ドルに成長すると予想されます。予測される成長は、市場競争、バイオシミラーの影響、病気の蔓延予測、ヘルスケア政策の変更、新興市場、臨床試験への注目の高まりによって推進されます。主な動向には、サプライチェーン管理の進歩、世界の拡大、患者教育、償還ポリシーの進化、業界の統合などが含まれます。

慢性腎臓病の有病率の増加により、市場でのエリスロポエチンの需要が高まると予想されます。慢性腎臓病の増加により、赤血球の生成を刺激して免疫力の向上を助けるエリスロポエチンの投与が必要となっています。 2021年 3月の疾病管理予防センターの報告書では、米国の成人の約15%（3,700万人に相当）が慢性腎臓病（CKD）を患っていると推定されていることが明らかになりました。有病率は65歳以上（38％）で高く、次いで45～64歳（13％）、18～44歳（7％）となっています。慢性腎臓病に起因する貧血状態はエリスロポエチンの需要増加に寄与し、それによって市場の成長を促進します。

エリスロポエチン市場の成長は、エリスロポエチン医薬品の製造と販売を管理する厳しい規制によって妨げられる可能性があります。欧州共同体（EC）では、先進医薬品、特に組換えDNA技術などのバイオテクノロジープロセスを使用して製造された医薬品は、ECが発行した規制（EC）No. 726/04に概説されている販売承認（MA）規制に準拠する必要があります。エリスロポエチンを含むバイオシミラーの規制状況は複雑で、主に欧州医薬品庁（EMEA）によって確立されたガイドラインによって管理されています。さらに、組換えヒトエリスロポエチン（rHuEPO）は、EMEAによって定義されている品質、臨床、非臨床の側面をカバーする規制に加えて、その製品クラス内の特定のガイドラインを遵守する必要があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のエリスロポエチン（EPO）市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• エポエチンアルファ
• エポエチンベータ
• ダルベポエチンアルファ
• その他の製品
• 世界のエリスロポエチン（EPO）市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• バイオロジクス
• バイオシミラー
• 世界のエリスロポエチン（EPO）市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• がん
• 血液学
• 腎臓病
• 神経内科
• その他の用途

第7章 地域および国の分析

• 世界のエリスロポエチン（EPO）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のエリスロポエチン（EPO）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エリスロポエチン（EPO）市場の競合情勢
• エリスロポエチン（EPO）市場企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F Hoffmann-La Roche Ltd.
  • Roche Holding AG
  • Novartis International AG

第31章 その他の大手および革新的な企業

• LG Life Sciences Ltd.
• LG Chem Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Chugai Pharmaceutical Co. Ltd.
• Meiji Seika Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Kyowa Kirin Co. Ltd.
• Dr Reddy's Laboratories Ltd.
• 3SBio Inc.
• Celltrion Inc.
• Watson Pharmaceuticals Inc.
• Biocon Limited
• Emcure Pharmaceuticals Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Erythropoietin (EPO) is a glycoprotein hormone naturally produced by the peritubular cells of the kidney, stimulating the production of red blood cells. It is utilized in the treatment of anemia, a condition characterized by a shortage of red blood cells. Symptoms of anemia, such as weakness, fatigue, and shortness of breath, arise due to the crucial role of red blood cells in delivering oxygen to tissues and organs.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports from The Business Research Company that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to several factors, including increased patient education and awareness, consolidation within the pharmaceutical industry, policies related to healthcare reimbursement, expansion of the market coupled with demand growth, and the impact of patent expiration and entry of biosimilar products.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The forecasted growth is driven by market competition, biosimilar impact, disease prevalence projections, healthcare policy changes, emerging markets, and increased focus on clinical trials. Key trends include supply chain management advancements, global expansion, patient education, reimbursement policy evolution, and industry consolidation.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for erythropoietin in the market. The rise in cases of chronic kidney disease necessitates the administration of erythropoietin, which stimulates the production of red blood cells, aiding in immune improvement. A report from the Centers for Disease Control and Prevention in March 2021 revealed that approximately 15% of adults in the United States, equating to 37 million people, were estimated to have chronic kidney disease (CKD). The prevalence is higher among individuals aged 65 or older (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%). The anemia conditions resulting from chronic kidney diseases contribute to an increased demand for erythropoietin, thereby fostering market growth.

The growth of the erythropoietin market may be hindered by stringent regulations governing the production and sales of erythropoietin drugs. In the European Community (EC), advanced medicinal products, especially those manufactured using biotechnological processes such as recombinant DNA technology, must comply with marketing authorization (MA) regulations outlined in Regulation (EC) No. 726/04 issued by the EC. The regulatory landscape for biosimilars, including erythropoietin, is intricate and primarily governed by guidelines established by the European Medicines Agency (EMEA). Additionally, recombinant human erythropoietin (rHuEPO) must adhere to specific guidelines within its product class, in addition to regulations covering quality, clinical, and non-clinical aspects, as defined by the EMEA.

The anticipated growth of the erythropoietin market is expected to be driven by the increasing incidence of hematologic cancer. Hematologic cancer constitutes a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, thereby alleviating anemia in cancer patients, particularly those undergoing chemotherapy. For instance, in 2023, the American Cancer Society estimates that leukemia is expected to affect 59,610 Americans and cause 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are projected to impact 80,550 people in the United States, resulting in 20,180 deaths. Consequently, the increasing prevalence of hematologic cancers is driving the forward momentum of the erythropoietin market.

Major players in the erythropoietin market are introducing innovative products such as Yi Bao (Human Erythropoietin for Injection) to drive business growth, enhance productivity, and explore new markets. Yi Bao is a recombinant human erythropoietin produced using CHO cells. Wanbang Biopharmaceuticals Co. Ltd., a China-based pharmaceutical company, obtained approval from the National Medical Products Administration (NMPA) in September 2021 for Yi Bao's use in treating anemia caused by chemotherapy in patients with non-myeloid malignancies. Yi Bao closely resembles the imported innovator drug, exhibiting precise efficacy and fewer side effects.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods PLC, DuPont de Nemours Inc., Kerry Group PLC, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International PLC, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

North America was the largest region in the erythropoietin (EPO) market in 2023. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erythropoietin (EPO) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erythropoietin (epo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erythropoietin (epo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Epoetin-alfa; Epoetin-beta; Darbepoetin-alfa; Other Products
• 2) By Drug Class: Biologist; Biosimilar
• 3) By Application: Cancer; Hematology; Renal diseases; Neurology; Other Applications
• Companies Mentioned: BASF SE; Hoffmann-La Roche AG; Merck Sharp & Dohme LLC; Sanofi SA; Thermo Fisher Scientific Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Erythropoietin (EPO) Market Characteristics

3. Erythropoietin (EPO) Market Trends And Strategies

4. Erythropoietin (EPO) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Erythropoietin (EPO) Market Size and Growth

• 5.1. Global Erythropoietin (EPO) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Erythropoietin (EPO) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Erythropoietin (EPO) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Erythropoietin (EPO) Market Segmentation

• 6.1. Global Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Other Products
• 6.2. Global Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biologis
• Biosimilar
• 6.3. Global Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cancer
• Hematology
• Renal diseases
• Neurology
• Other Applications

7. Erythropoietin (EPO) Market Regional And Country Analysis

• 7.1. Global Erythropoietin (EPO) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Erythropoietin (EPO) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Erythropoietin (EPO) Market

• 8.1. Asia-Pacific Erythropoietin (EPO) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Erythropoietin (EPO) Market

• 9.1. China Erythropoietin (EPO) Market Overview
• 9.2. China Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Erythropoietin (EPO) Market

• 10.1. India Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Erythropoietin (EPO) Market

• 11.1. Japan Erythropoietin (EPO) Market Overview
• 11.2. Japan Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Erythropoietin (EPO) Market

• 12.1. Australia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Erythropoietin (EPO) Market

• 13.1. Indonesia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Erythropoietin (EPO) Market

• 14.1. South Korea Erythropoietin (EPO) Market Overview
• 14.2. South Korea Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Erythropoietin (EPO) Market

• 15.1. Western Europe Erythropoietin (EPO) Market Overview
• 15.2. Western Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Erythropoietin (EPO) Market

• 16.1. UK Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Erythropoietin (EPO) Market

• 17.1. Germany Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Erythropoietin (EPO) Market

• 18.1. France Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Erythropoietin (EPO) Market

• 19.1. Italy Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Erythropoietin (EPO) Market

• 20.1. Spain Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Erythropoietin (EPO) Market

• 21.1. Eastern Europe Erythropoietin (EPO) Market Overview
• 21.2. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Erythropoietin (EPO) Market

• 22.1. Russia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Erythropoietin (EPO) Market

• 23.1. North America Erythropoietin (EPO) Market Overview
• 23.2. North America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Erythropoietin (EPO) Market

• 24.1. USA Erythropoietin (EPO) Market Overview
• 24.2. USA Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Erythropoietin (EPO) Market

• 25.1. Canada Erythropoietin (EPO) Market Overview
• 25.2. Canada Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Erythropoietin (EPO) Market

• 26.1. South America Erythropoietin (EPO) Market Overview
• 26.2. South America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Erythropoietin (EPO) Market

• 27.1. Brazil Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Erythropoietin (EPO) Market

• 28.1. Middle East Erythropoietin (EPO) Market Overview
• 28.2. Middle East Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Erythropoietin (EPO) Market

• 29.1. Africa Erythropoietin (EPO) Market Overview
• 29.2. Africa Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Erythropoietin (EPO) Market Competitive Landscape And Company Profiles

• 30.1. Erythropoietin (EPO) Market Competitive Landscape
• 30.2. Erythropoietin (EPO) Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Roche Holding AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis International AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Erythropoietin (EPO) Market Other Major And Innovative Companies

• 31.1. LG Life Sciences Ltd.
• 31.2. LG Chem Ltd.
• 31.3. Amgen Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Sandoz International GmbH
• 31.6. Chugai Pharmaceutical Co. Ltd.
• 31.7. Meiji Seika Pharma Co. Ltd.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Kyowa Kirin Co. Ltd.
• 31.10. Dr Reddy's Laboratories Ltd.
• 31.11. 3SBio Inc.
• 31.12. Celltrion Inc.
• 31.13. Watson Pharmaceuticals Inc.
• 31.14. Biocon Limited
• 31.15. Emcure Pharmaceuticals Ltd.

32. Global Erythropoietin (EPO) Market Competitive Benchmarking

33. Global Erythropoietin (EPO) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Erythropoietin (EPO) Market

35. Erythropoietin (EPO) Market Future Outlook and Potential Analysis

• 35.1 Erythropoietin (EPO) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Erythropoietin (EPO) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Erythropoietin (EPO) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer